In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Affimed signs innate cell antibody engager deal with Genentech

Executive Summary

Affimed NV and Roche’s Genentech Inc. agreed to discover and conduct early- and late-stage research on innate immune cell--natural killer (NK) cell and T-cell--immunotherapies against certain Genentech-selected targets for various solid and hematological tumors. Genentech will take over clinical development and hold exclusive global commercialization rights; it is also responsible for related costs.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies